{"filings":[{"id":1922637,"accession_number":"0000805928-26-000091","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-07-29T11:11:02+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q2 revenue $69.7M (+23% YoY), raises FY2026 guidance to at least $279M (24% growth)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $69.7M, up 23.1% YoY; net loss $1.5M ($0.03/sh) vs net income $0.6M ($0.01/sh) in Q2 2025.","Adjusted net income $7.3M ($0.12/sh) vs $5.7M ($0.12/sh) YoY; adjusted EBITDA $8.4M vs $9.3M.","Raises FY2026 revenue guidance to at least $279M (24% growth); gross margin guidance at least 73%; expects positive free cash flow.","Gross margin 72.7% vs 74.2% due to product mix shift from >50% Breast growth.","Cash and investments $113.4M, up $9.8M from Q1 2026; minority stake in Trace Biosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1223396,"accession_number":"0000805928-26-000081","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-06-23T20:39:20+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axogen shareholders elect eight directors, ratify auditors, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with 97.3%-99.6% votes for; Paul Thomas 39,087,824 for.","Ratification of Deloitte & Touche as FY2026 auditor approved with 45,296,698 for (99.9%).","Advisory vote on named executive officer compensation passed with 38,606,031 for (96.4%).","Meeting held June 23, 2026; 45,364,808 shares present of 53,177,824 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98973,"accession_number":"0000805928-26-000051","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.","GAAP net loss $19.6M ($0.38/share); adjusted net income $4.1M ($0.07/share) vs adjusted net loss $0.9M in Q1 2025.","Raises full-year 2026 revenue guidance to at least 20% growth or $270M; expects gross margin 74%-76% and positive free cash flow.","Closed upsized public offering netting $133.3M; used $69.7M to repay Oberland loan; cash & investments rose to $103.6M.","Received positive coverage decisions from Cigna and Elevance Health; CMS new Level 3 Nerve Procedure Code boosts Avance reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":61457000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114718,"accession_number":"0000805928-26-000028","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).","FY2025 revenue $225.2M (+20.2% YoY); adjusted net income $14.4M ($0.29/sh); adjusted EBITDA $27.9M.","FDA approved Avance BLA on Dec 3, 2025; CMS new Level 3 code raises Avance facility reimbursement 40% to $8,965.","Closed upsized public offering of 4.6M shares for $133.3M net; $69.7M used to repay Oberland loan facility.","2026 guidance: revenue at least $265.7M (+18% YoY); gross margin 74%-76%; expects positive free cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":225208000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114717,"accession_number":"0000805928-26-000026","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Axogen prices $124M public offering at $31/share; proceeds to pay off $69.7M credit facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of upsized 4M share offering at $31.00/share for gross proceeds of ~$124M (assuming no over-allotment).","Net proceeds used primarily to repay ~$69.7M term loan with Oberland Capital, terminating that credit facility.","Underwriters granted 30-day option to purchase up to an additional 600K shares (~$18.6M).","Offering expected to close on January 23, 2026; Wells Fargo and Mizuho are lead book-running managers.","Remaining net proceeds for working capital, capital expenditures, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114716,"accession_number":"0000805928-26-000004","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen reports preliminary Q4 revenue $59.9M (+21.3% YoY); full-year $225.2M (+20.2%); FDA BLA approval for Avance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).","Gross margin expected above 74% for Q4 and FY 2025; includes ~$1.9M one-time costs related to Avance BLA approval, 67% non-cash.","Cash, equivalents, restricted cash, and investments ~$45.5M at Dec 31, 2025, up ~$6.0M from end of 2024.","FDA approved Biologics License Application for Avance (acellular nerve allograft) on Dec 3, 2025.","Growth driven by commercial strategy targeting Extremities and OMF-Head & Neck, and increased Resensation penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":225208000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131096,"accession_number":"0000805928-25-000146","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Axogen raises CFO Hartley's base salary 7%, bonus target to 60%, adds 2-year non-compete","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Lindsey Hartley's annual base salary increased by 7% effective January 1, 2026.","Target bonus opportunity raised from 50% to 60% of base salary under annual incentive program.","Entered Amended Agreement with two-year post-employment non-competition covenant.","New compensation and agreement effective January 1, 2026 and December 5, 2025 respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131095,"accession_number":"0000805928-25-000140","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Axogen receives FDA approval of BLA for Avance nerve allograft under Accelerated Approval pathway","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Biologics License Application for Avance (acellular nerve allograft) for sensory, mixed, motor nerve discontinuities in adults and pediatric patients 1 month+.","Indications for sensory gaps >25mm and mixed/motor gaps approved under Accelerated Approval pathway; continued approval depends on confirmatory studies.","Commercial launch of licensed Avance expected early Q2 2026; product remains available under current tissue framework until then.","CEO Michael Dale says approval strengthens regulatory footing and confirms Avance as safe, pure, potent therapeutic option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131094,"accession_number":"0000805928-25-000128","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.","Gross margin improved to 76.6% from 74.9% YoY; adjusted EBITDA $9.2M vs $6.5M.","Raised full-year revenue guidance to at least $222.8M (≥19% growth); gross margin reaffirmed 73-75%.","FDA PDUFA for Avance Nerve Graft BLA extended to Dec 5, 2025; AAHS and ASRM issued position statements recognizing nerve allografts.","Added 18.1M covered lives in 2025; commercial payer coverage now over 64%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":165304000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147682,"accession_number":"0000805928-25-000112","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA extends PDUFA date for Axogen's Avance Nerve Graft BLA to Dec 5, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA deemed Axogen's August 22 submission a Major Amendment, extending PDUFA goal date by three months to Dec 5, 2025.","FDA now anticipates providing product labeling feedback in November 2025.","Submission included substantial new manufacturing and facility data not previously reviewed by the Agency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147681,"accession_number":"0000805928-25-000104","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.","Adjusted EPS $0.12 vs $0.05 YoY; adjusted EBITDA $9.3M vs $5.6M; gross margin 74.2% up from 73.8%.","Raised FY25 revenue guidance to at least 17% growth, or $219M; reiterates gross margin 73-75% and net cash flow positive.","FDA accepted BLA for Avance Nerve Graft; PDUFA date Sept 5, 2025; pre-licensing inspection and regulatory milestones completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":105222000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166356,"accession_number":"0000805928-25-000095","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axogen shareholders approve all five proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected eight directors to one-year terms; all received >26.7M votes for.","Ratified Deloitte & Touche as independent auditor for FY2025; 37.0M for, 36K against.","Approved advisory say-on-pay resolution with 28.7M for, 3.2M against.","Approved amendment to 2019 LTI Plan increasing authorized shares from 10.5M to 13.4M.","Adopted 1-year frequency for future say-on-pay votes with 31.1M votes for 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166355,"accession_number":"0000805928-25-000062","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Axogen Q1 revenue $48.6M (+17.4% YoY); appoints Lindsey Hartley as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $48.6M, up 17.4% YoY; net loss $3.8M ($0.08/share) vs $6.6M loss in Q1 2024.","Adjusted net loss $0.9M ($0.02/share) vs $2.7M loss; adjusted EBITDA $2.9M vs $1.0M prior year.","Gross margin 71.9% down from 78.8% due to product costs and inventory write-offs; cash $28.1M.","CFO Nir Naor steps down May 11; Lindsey Hartley appointed effective May 12; salary $440k, target bonus 50%.","FY guidance maintained: revenue growth 15-17%, gross margin 73-75%, net cash flow positive."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":48560000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166354,"accession_number":"0000805928-25-000053","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Axogen anticipates minimal impact from new U.S. tariffs on operations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["President Trump announced broad tariff plan on April 2, 2025.","Axogen states vast majority of sales are domestic; manufacturing also domestic.","Imported materials costs are minimal, limiting tariff exposure.","Company expects no material impact from tariffs or retaliatory actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183795,"accession_number":"0000805928-25-000024","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Axogen posts updated corporate presentation on investor website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated investor presentation dated March 4, 2025 posted to Axogen's website.","Presentation may be used in conversations with analysts and investors.","No specific financial or operational details from the presentation disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183794,"accession_number":"0000805928-25-000010","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.","Q4 net income $0.4M ($0.01 EPS) vs net loss $3.9M prior year; adjusted net income $3.5M ($0.07 EPS).","Full-year 2024 revenue $187.3M (+17.8% YoY); adjusted EBITDA $19.8M vs -$1.1M in 2023.","FDA accepted BLA for Avance Nerve Graft; PDUFA goal date Sept 5, 2025; anticipates approval.","2025 guidance: revenue growth 15-17%, gross margin 73-75%, expects positive net cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":187338000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183793,"accession_number":"0000805928-25-000006","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen reports Q4 2024 revenue $49.4M (+15.1% YoY); FY 2024 revenue $187.3M (+17.8%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue expected $49.4M, up 15.1% YoY; full-year 2024 revenue $187.3M, up 17.8%.","Full-year gross margin expected above 75.5%; cash and investments $39.5M, up $2.5M from 2023.","Growth driven by commercial execution in Extremities, OMF-Head & Neck, and Resensation adoption.","Investor Day scheduled for March 4, 2025 to discuss strategic priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":187338000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200394,"accession_number":"0000805928-24-000135","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.","Net loss $1.9M ($0.04/shr) vs $4.1M ($0.10/shr); adjusted net income $3.1M ($0.07/shr).","Adjusted EBITDA $6.5M vs $2.4M in Q3 2023; cash $30.5M at quarter end.","FDA accepted BLA for Avance Nerve Graft under standard review; PDUFA date Sept 5, 2025; no advisory committee planned.","2024 revenue guidance reaffirmed $182M-$186M; expects high end of gross margin range and cumulative net cash flow positive."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":137933000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216424,"accession_number":"0000805928-24-000127","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Axogen completes BLA submission to FDA for Avance Nerve Graft; priority review requested","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA submission for Avance Nerve Graft completed under rolling review process on Sept. 6, 2024.","Company requested priority review; if granted, review timeline could be 6 months vs. standard 10 months.","Avance previously received RMAT designation from FDA under 21st Century Cures Act.","FDA expected to notify acceptance and confirm review timeline within approximately 60 days.","Company on track for FDA approvability determination between April and September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216423,"accession_number":"0001193125-24-197821","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.","Paul Thomas appointed Chair of the Board, effective August 9, 2024; he joined the Board in 2020.","Dale receives $765k base salary, 100% target bonus, and 600,000 PSUs tied to stock price goals and Avance Nerve Graft BLA approval.","Dale has 30+ years med device experience, most recently President of structural heart at Abbott (NYSE: ABT).","Zaderej remains in advisory role for nine months under a previously disclosed Transition and Separation Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216422,"accession_number":"0000805928-24-000107","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.","Adjusted net income $2.0M ($0.05/share); adjusted EBITDA $5.6M vs loss $0.2M.","FY2024 revenue guidance raised to $182-186M; gross margin guidance adjusted to 74-76%.","Rolling BLA submission for Avance Nerve Graft initiated; expects completion Q3 2024, potential approval mid-2025.","Launched Avive+ Soft Tissue Matrix in June; Core accounts up 18.7% to 412."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":89289000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235996,"accession_number":"0001193125-24-157679","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K/A","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axogen shareholders elect all nine directors, approve LTIP share increase to 10.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; broker non-votes 4,270,312 on each proposal.","Ratification of Deloitte as auditor: 35,220,045 for, 1,254,727 against.","Advisory say-on-pay approved: 22,655,899 for, 9,494,316 against.","Third amended 2019 LTIP approved; shares increased from 8M to 10.5M: 22,846,399 for, 9,336,789 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235998,"accession_number":"0000805928-24-000079","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Axogen shareholders vote down proposal to increase LTIP share reserve; Freitag departs board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gregory Freitag not re-nominated; Board accelerated vesting of 11,904 RSUs and options for 20,436 shares.","All nine director nominees elected; average 'For' votes ~27.4M vs ~4.6M withheld.","Ratification of Deloitte as auditor approved (35.2M for, 1.3M against, 20k abstain).","Advisory say-on-pay approved (22.7M for, 9.5M against, 74k abstain).","Proposal to increase LTIP shares from 8M to 10.5M failed (22.8M for, 9.3M against, 41k abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235997,"accession_number":"0000805928-24-000070","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q1 2024 revenue $41.4M (+12.9% YoY); net loss narrows to $6.6M; adj EBITDA turns positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.4M, up 12.9% YoY; gross margin improved to 78.8% from 77.7%.","Net loss $6.6M ($0.15/sh) vs $7.1M ($0.17/sh) in Q1 2023; adjusted net loss $2.7M ($0.06/sh).","Adjusted EBITDA positive at $1.0M vs loss of $3.8M in prior year.","Cash & investments $23.6M as of March 31, 2024, down from $37.0M at Dec 31, 2023.","Reaffirmed FY2024 revenue guidance $177M-$181M; gross margin 76%-79%; expects positive net cash flow Apr-Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":41378000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253749,"accession_number":"0000805928-24-000037","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Axogen Chief R&D Officer Scopelianos resigns; transition consulting through Dec 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Angelo Scopelianos resigns as Chief R&D Officer effective no later than March 31, 2024.","He will consult up to 10 hrs/wk from Apr 1 to Dec 31, 2024 for $9,079.16/month plus a $75,000 one-time payment if through Oct 1.","Scopelianos receives his 2023 bonus of $228,385.26 on March 15, 2024.","Unvested stock options continue vesting through consulting period; RSUs and unvested PSUs cease at separation.","Product development duties assumed by VP Stacy Arnold, who reports directly to CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253748,"accession_number":"0000805928-24-000029","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Axogen posts updated corporate presentation to website on March 5, 2024","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["The presentation was posted to Axogen's investor relations website for use with analysts and investors.","No specific financial or operational updates are disclosed in the limited exhibit text provided.","The presentation is dated March 5, 2024, and the filing is under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253747,"accession_number":"0000805928-24-000025","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen reports Q4 2023 revenue $42.9M (+18.7% YoY); 2024 revenue guidance $177-181M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $3.9M ($0.09/share) vs $5.4M loss in Q4 2022; adjusted EBITDA turned positive at $0.6M.","Full-year 2023 revenue $159.0M (+14.7% YoY); net loss $21.7M vs $28.9M in 2022.","Gross margin declined: Q4 78.7% vs 83.0%; FY 80.4% vs 82.6%. Guidance expects 76-79% for 2024.","FDA pre-BLA agreement for Avance nerve graft; rolling submission in Q3 2024, potential approval mid-2025.","Avive+ Soft Tissue Matrix launch planned in Q2 2024; core accounts grew 13.3% to 376."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253746,"accession_number":"0000805928-24-000013","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Axogen posts updated corporate presentation; no material changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an updated corporate presentation to its IR website on January 5, 2024.","Presentation covers business strategy, product portfolio, and forward-looking statements.","No specific financial results, guidance changes, or material events are included in the filing excerpt.","This is a routine investor update filed under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253744,"accession_number":"0000805928-24-000011","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K/A","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Axogen CFO Peter Mariani departs; receives $473K severance, $25K/month consulting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Peter Mariani separated effective Dec 22, 2023; lump sum severance $472,999.54 (12 months base) plus bonus equivalent $60,437.83.","Consulting agreement for 12 months at $25,000/month as independent contractor; unvested equity forfeited, 298,319 vested options extended.","Company pays COBRA premiums for 12 months; consulting period can be terminated for cause.","Performance-based RSUs to settle based on actual performance; D&O tail coverage provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253745,"accession_number":"0000805928-24-000005","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Axogen reports preliminary Q4 revenue $42.7M (+18% YoY); CEO Karen Zaderej to retire by Jan 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Q4 revenue $42.7M (+18% YoY); FY2023 revenue $158.8M (+15% YoY) at high end of $154-159M guidance.","Gross margin for FY2023 expected ~80%; 375 Core Accounts (+13% YoY); 116 direct sales reps.","CEO Karen Zaderej to retire by Jan 2025; Board will search for successor; she will consult for 9 months after transition.","BLA submission for Avance Nerve Graft on track for H1 2024; Axoguard HA+ and Avive+ product rollouts planned.","Avance Nerve Graft surpassed 100,000 implants since launch; strong commercial execution cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271183,"accession_number":"0000805928-23-000156","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axogen appoints Kathy Weiler to its board, effective Dec 20, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 10; Weiler serves on Governance, Nominating & Sustainability and Quality, Compliance & Portfolio committees.","Weiler is EVP, Chief Commercial & Growth Officer at Amwell (NYSE: AMWL); 20+ years in healthcare commercial leadership.","Initial stock option grant of $275k value vesting over 3 years; annual equity grants of $150k (half options, half RSUs) vesting 1 year.","Compensation includes quarterly cash retainer of $10,000 plus $1,250 per committee served."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271182,"accession_number":"0000805928-23-000151","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axogen appoints Nir Naor as CFO; Peter Mariani departs; FY2023 revenue guidance reaffirmed $154-159M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nir Naor appointed CFO effective Dec 4, 2023, replacing Peter Mariani who stepped down at Board's request.","Naor receives base salary $475K, target bonus 60%, and inducement grant of 300,000 RSUs vesting over 3 years.","Mariani remains for brief transition; separation terms under discussion.","Company reaffirms FY2023 revenue guidance of $154-159M (11-15% growth) and gross margin ~80%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271181,"accession_number":"0000805928-23-000146","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q3 revenue $41.3M (+12% YoY); maintains FY2023 guidance $154-159M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.3M (+12% YoY); scheduled non-trauma grew ~20%, emergent trauma mid-single digits.","Net loss $4.1M ($0.10/sh); adjusted net income $0.7M ($0.01/sh); Adj. EBITDA $2.4M vs $0.4M.","Gross margin 80.5% (down from 83.3%); FY2023 gross margin expected ~80%.","Cash & investments $38.6M; new processing facility began tissue processing in Aug.","Core Accounts 372 (+12% YoY); revenue from Core Accounts now ~65% of total."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":116090000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288051,"accession_number":"0000805928-23-000128","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Axogen VP of Operations Mike Donovan to retire March 22, 2024; responsibilities to Todd Puckett","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mike Donovan, VP of Operations, to retire effective March 22, 2024; transition planned.","Todd Puckett (VP, Manufacturing, non-executive) to assume Donovan's responsibilities around March 25.","Donovan qualifies for Qualified Retirement; options on 98,245 shares and 85,750 RSUs continue vesting.","Performance stock units will vest prorated based on actual performance and employment days.","Donovan is at least 60 with 10+ years service; notice given per award agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288050,"accession_number":"0000805928-23-000102","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Axogen shareholders reject incentive plan share increase at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to increase LTIP shares from 8M to 10.5M failed with 11.3M for vs 18.6M against (excluding broker non-votes).","ESPP share increase (600K to 1.2M) approved with 27.4M for, 2.6M against.","Bylaws amendment to set board size range of 7-11 members approved with 34.1M for, 0.9M against.","All nine director nominees elected; highest withheld was Guido Neels with 7.2M withheld.","Say-on-pay passed with 28.6M for, 1.4M against; auditor ratification approved with 34.9M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288049,"accession_number":"0000805928-23-000087","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q2 revenue $38.2M (+11% YoY); net loss narrows to $6.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.2M in Q2 2023, up 11% vs Q2 2022; scheduled procedures grew >20%, trauma low-single-digit.","Net loss $6.7M ($0.16 per share) vs $7.7M loss a year ago; adjusted net loss $1.3M ($0.03 per share).","Gross margin 81.1% (vs 81.8% YoY); cash & investments $40.8M; $3.6M capex for new Dayton processing facility.","FY 2023 revenue guidance maintained at $154M-$159M (11-15% growth); gross margin expected ~80% for full year.","Pilot launched Axoguard HA+ Nerve Protector; BLA submission for Avance expected Q1-Q2 2024 with target approval H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":74819000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308468,"accession_number":"0000805928-23-000075","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["1.0","2.03","1.01","9.01"],"status":"ready","headline":"Axogen amends term loan to transition from LIBOR to Adjusted Term SOFR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 1 executed June 29, 2023 changes benchmark rate from LIBOR to Adjusted Term SOFR plus spread adjustment.","Parties: Axogen, Axogen Corporation, Axogen Processing Corp., lender TPC Investments II LP, admin agent Argo SA LLC.","Loan agreement otherwise unchanged; guarantees and security interests reaffirmed.","Amendment effective upon execution; conditions included lender consent and payment of documented expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308467,"accession_number":"0000805928-23-000049","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Axogen Q1 revenue up 18% to $36.7M; net loss narrows; FDA clears Axoguard HA+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $36.7M (+18% YoY); net loss $7.1M vs $11.5M prior year.","Adjusted net loss $4.1M ($0.10/share) vs $8.5M ($0.20/share) prior year.","FDA 510(k) clearance for Axoguard HA+ Nerve Protector; pilot launch Q2, full launch Q3.","Full-year 2023 revenue guidance reaffirmed at $154M-$159M.","Cash and investments $44.1M at March 31, down from $55.0M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":36664000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308466,"accession_number":"0000805928-23-000046","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Axogen sets 2023 annual meeting for Aug 15; shareholder proposals due May 11","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2023 Annual Shareholders' Meeting scheduled for August 15, 2023.","Shareholder proposals and director nominations must be received by May 11, 2023 at 5:00 p.m. ET.","Meeting date is more than 30 days after prior year's meeting; new deadline provided for clarity.","Nominations and proposals must comply with Company's Bylaws as filed on Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327277,"accession_number":"0000805928-23-000017","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen reports Q4 revenue $36.2M (+17% YoY); guides FY2023 revenue $154M-$159M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $36.2M, up 17% YoY; gross margin 83.0%; net loss $5.4M ($0.13/sh).","Full-year 2022 revenue $138.6M, up 12% YoY; adjusted net loss $12.6M.","Cash and investments $55.0M at Dec 31, 2022; notes $8M at SVB now accessible.","2023 revenue guidance $154M-$159M; gross margin expected ~80% by Q4 2023.","Active Accounts 968; Core Accounts 332; 115 direct sales representatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327276,"accession_number":"0000805928-23-000015","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Axogen's $8M SVB deposits fully protected; moving other assets to JP Morgan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Axogen had $8M cash at SVB, its sole depositor; FDIC guarantees full access as of March 13.","Majority of other cash/investments held in U.S. Bank custodial accounts advised by SVB Asset Management.","Company opening new brokerage/operations accounts with JP Morgan to move all held funds.","Believes existing cash plus product sales sufficient for at least 12 months.","SVB closed by California regulator March 10; FDIC appointed receiver."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327275,"accession_number":"0000805928-23-000003","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen reports preliminary Q4 2022 revenue of $36.1M, up 16% YoY ex-Avive; FY22 $138.5M, up 12%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $36.1M, up 14% reported or 16% excluding Avive; FY22 $138.5M, up 9% reported or 12% ex-Avive.","Cash and investments ~$55.0M at Dec 31, down from $59.4M at Sep 30; includes $5.3M capex for new Dayton, OH facility.","115 direct sales reps (flat YoY); 332 Core Accounts (+1% sequential); 968 Active Accounts (+2% sequential).","Surpassed 75,000 Avance Nerve Graft implants since launch; BLA submission planned for H2 2023.","Reaffirms FY22 gross margin above 80%; full FY23 outlook to be provided on March 14, 2023 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":138584000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344994,"accession_number":"0000805928-22-000114","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q3 revenue $37.0M (+18% YoY); net loss narrows to $4.3M; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.3M ($0.10/sh) vs $7.1M loss ($0.17/sh) in Q3 2021; adjusted net loss $0.4M ($0.01/sh).","Adjusted EBITDA turned positive at $0.4M vs loss of $2.5M YoY.","Narrows FY2022 revenue guidance to $137.5M-$140.0M (prior $135M-$142M); gross margin above 80%.","Appointed William Burke to Board and Audit Committee; Adrian Tyndall joins Dec 13 as Mark Gold retires.","Core accounts 331 (+11% sequentially); cash $59.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":102420000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344993,"accession_number":"0000805928-22-000110","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axogen appoints Adrian Tyndall to board; founding director Mark Gold retires Dec 13","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Founding director Dr. Mark Gold resigns effective Dec 13, 2022; no dispute cited.","Dr. Adrian Tyndall appointed to board effective Dec 13; will serve on Quality, Compliance & Portfolio Committee.","Tyndall is Exec VP for Health Affairs & Dean of Morehouse School of Medicine; former UF College of Medicine interim dean.","Tyndall receives standard director compensation: $10k quarterly cash retainer, $1.25k committee retainer, $275k initial option grant vesting over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361479,"accession_number":"0001140361-22-030901","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-08-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Axogen expands Burleson facility and amends tissue processing agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Amendment to Burleson lease doubles space to 5,000 sq ft, extends term to September 2027.","Monthly base rent starts at $4,583 (Oct 2022) and increases to $5,464 (Oct 2026-2027).","Eighth Amendment to License and Services Agreement with Community Blood Center updates termination notice and decommission duties.","Processing fees set: $300.48 per nerve tissue debridement batch, $1,120.04 per nerve processing batch, $150 birth tissue debridement, $1,500 birth tissue processing.","Licensor will provide cleaning/sterilization services for product processed at Licensee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361478,"accession_number":"0000805928-22-000100","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Axogen Q2 revenue $34.5M (+3% YoY); adjusted net loss narrows to $2.6M; reaffirms FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $34.5M, +3% YoY; ex-Avive (suspended June 2021) revenue grew 9%.","Gross margin 81.8% vs 78.9% in Q2 2021 (included $1.4M Avive write-down).","Adjusted net loss $2.6M ($0.06/share) vs loss $3.7M ($0.09/share) in Q2 2021.","Cash+investments $64.3M, down from $73.7M at March 2022; $3.9M capex for Dayton facility.","FY2022 revenue guidance reaffirmed at $135-142M; gross margin expected above 80%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":65461000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361477,"accession_number":"0001140361-22-026256","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-07-18T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Axogen announces CCO departure, preliminary Q2 rev $34.4M (+2% YoY)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Sandberg, Chief Commercial Officer, terminated without cause effective July 19, 2022; eligible for severance per employment agreement.","Preliminary unaudited Q2 2022 revenue ~$34.4M, up 2% YoY (8% ex-Avive divestiture).","Full-year 2022 revenue guidance reaffirmed at $135-142M; gross margin above 80%.","Sales organization will report directly to CEO Karen Zaderej; company plans to appoint a CMO in coming months.","Full Q2 results and conference call scheduled for August 3, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361476,"accession_number":"0001140361-22-025652","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Axogen appoints William Burke to Board of Directors, effective July 11, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Burke, former EVP & CFO of Haemonetics, appointed as director effective July 11, 2022.","Burke will chair the Audit Committee; board committees were reconstituted.","Burke brings 25+ years of finance leadership from Medtronic, Covidien, and Haemonetics.","Compensation includes $10,000 quarterly retainer, $5,000 as Audit Committee chair, plus equity grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380803,"accession_number":"0000805928-22-000061","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Axogen stockholders approve expanded LTIP, reject bylaw amendment at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Second Amended 2019 LTIP, increasing shares from 5.5M to 8.0M.","Bylaw amendment to allow board to set director count rejected (9.65M for, 20.85M against).","Eight directors elected; Amy Wendell received the most withheld votes (5.44M) but still elected.","Advisory say-on-pay approved with 21.96M for (71.7% of votes cast, excluding broker non-votes).","Deloitte & Touche ratified as auditor for FY2022 (34.99M for, 58,556 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380802,"accession_number":"0000805928-22-000054","cik":805928,"company_name":"Axogen, Inc.","ticker":"AXGN","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Axogen Q1 rev flat at $31M, net loss widens to $0.20/sh; Avance Phase 3 hits endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $31.0M flat YoY; adjusted net loss $8.5M ($0.20/sh) vs $3.1M ($0.08) prior year.","Cash and investments $73.7M at Mar 31, down from $90.3M at Dec 31, 2021.","Phase 3 RECON study of Avance Nerve Graft met primary endpoint for sensory function; BLA submission planned H2 2023.","Avance showed statistical superiority over conduits for gaps >12mm (p=0.021) and faster recovery (p=0.037).","2022 revenue guidance reaffirmed $135-142M; gross margin above 80%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":31007000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2120199958.4981904,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-04T23:59:59+00:00|380802"}